Alnylam Pharmaceuticals Inc (ALNY)vsSinovac Biotech Ltd (SVA)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
SVA
Sinovac Biotech Ltd
$6.47
0.00%
HEALTHCARE · Cap: $642.44M
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 627% more annual revenue ($3.71B vs $510.62M). SVA leads profitability with a 21.6% profit margin vs 8.5%. SVA trades at a lower P/E of 6.7x. SVA earns a higher WallStSmart Score of 78/100 (B+).
ALNY
Hold49
out of 100
Grade: D+
SVA
Strong Buy78
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Margin of Safety
+85.8%
Fair Value
$45.44
Current Price
$6.47
$38.97 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 42.3%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Every $100 of equity generates 25 in profit
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
3.0% revenue growth
3.5% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : SVA
The strongest argument for SVA centers on P/E Ratio, Price/Book, Operating Margin. Profitability is solid with margins at 21.6% and operating margin at 42.3%.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : SVA
The primary concerns for SVA are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while SVA is a value play — different risk/reward profiles.
ALNY carries more volatility with a beta of 0.38 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
SVA scores higher overall (78/100 vs 49/100), backed by strong 21.6% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Sinovac Biotech Ltd
HEALTHCARE · BIOTECHNOLOGY · China
Sinovac Biotech Ltd., a biopharmaceutical company, focuses on the research, development, manufacture and marketing of vaccines against human infectious diseases in the People's Republic of China. The company is headquartered in Beijing, the People's Republic of China.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?